The biopharmaceutical company's drug discovery and development program focuses on therapeutics derived from amphibian ribonucleases, with its lead drug product candidate, ONCONASE, currently being evaluated in human clinical trials for various forms of cancer. Tamir Biotechnology is also working on a new drug application for unresectable malignant mesothelioma and has completed a Phase I clinical trial for the treatment of non-small cell lung cancer. The company's goal is to discover and develop a new class of prophylactic and therapeutic drugs for the treatment of viruses and other pathological conditions, providing clinicians with improved antiviral drugs to treat various viral infections and better outcomes for their patients.